02563.HK
Beijing Biostar Pharms Co Ltd
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.40
−4.23%Oct 21, 2026, 02:02 UTC
Huahao Zhongtian announced that the first patient was dosed in a Phase III study of UTD2 capsules for HER2-negative advanced breast cancer.
Source: